Heart Failure Congestive Clinical Trial
Official title:
Effect of Omega 3 Supplementation on Brain Natriuretic Peptide (BNP) Serum Levels Functional Capacity and Systolic and Diastolic Function of Heart Failure Patients
In this double blinded study patients with resynchronization pacemaker- AICD were assigned to Omega3 and placebo randomly, results indicated that Omega3 had no more effect than placebo in mortality, BNP level and 6 minutes walk test.
Introduction: Widely used as lipid lowering agents, Omega 3 fatty acids have been
demonstrated to possess the potential to reduce the risk of cardiovascular events in
patients suffering from chronic heart conditions. In this double -blinded randomized
placebo-controlled clinical trial, we aim to investigate the possible beneficial effects of
Omega-3 supplements on echocardiographic parameters and brain natriuretic peptide (BNP)
plasma levels in patients suffering from congestive heart failure (CHF).
Methods and Materials: 100 patients with class II and III CHF, who had tri-chamber pacemaker
and automated defibrillator( CRT-AICD) were initially recruited among which 70 subjects
consented to participate. Subjects were randomly assigned and matched to two treatment
groups. 42 patients were allocated to a two gram/day dosing of omega-3 capsule while 28
subjects were allocated to the placebo group. Demographic features and BNP plasma levels,
6-minute walk test and echocardiographic parameters of patients were recorded at baseline
and at 6 months after implementation of treatment protocols. Data were further gathered and
analyzed to evaluate the beneficial effects of omega-3 supplements compared to placebo.
Conclusion: Beneficial effects of Omega-3 supplementation on CHF patients were not as
dramatic as initially presumed
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01966887 -
AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure
|
Phase 2 |